Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961071 · ClinicalTrials.gov registry record · Phase 1
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
A Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural, sponsored by Peter Stock.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT06961071 is a Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural that is actively recruiting participants, run by Peter Stock. The registered enrollment target is 3 participants, below the 199-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06961071, a Phase 1 study of Hypoparathyroidism and Hypoparathyroidism Postprocedural, is actively recruiting participants, sponsored by Peter Stock.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).
Conditions Studied
Interventions
- BIOLOGICAL Parathyroid Allotransplant
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2028-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961071
The ClinicalTrials.gov registry entry for NCT06961071 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (98% lower). The listed sponsor is Peter Stock, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypoparathyroidism appearing as the primary indexed condition, and to 1 intervention - of which Parathyroid Allotransplant is the first listed.
NCT06961071 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06961071 about?
NCT06961071 is a clinical study titled "Parathyroid Allotransplant for Treatment of Hypoparathyroidism". This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric ti...
What is the current status of trial NCT06961071?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2026-01-15. Estimated completion is 2028-01-15.
What conditions does trial NCT06961071 study?
This clinical trial studies the following conditions: Hypoparathyroidism, Hypoparathyroidism Postprocedural, Hypoparathyroidism Post-surgical.
What interventions are being tested in trial NCT06961071?
The interventions under investigation include: Parathyroid Allotransplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06961071?
This trial is sponsored by Peter Stock, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961071 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoparathyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
RECRUITING
-
Hypoparathyroidism Natural History Study
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
A Registry for Participants With Chronic Hypoparathyroidism
ACTIVE NOT RECRUITING
-
Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
ACTIVE NOT RECRUITING · Phase 2
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.